ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV

LONDON & SAN DIEGO–(BUSINESS WIRE)–ViiV HC and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to develop ultra-long-acting HIV medicines
Click here to view original post